UNLOXCYT™ (cosibelimab-ipdl)

About Sun Pharmaceutical

Sun Pharma's mission is to provide high-quality, affordable medicines globally, improving access and patient care. Its key achievement is transforming from a small startup in 1983 into a global pharmaceutical titan with a market cap exceeding $45 billion, largely through strategic acquisitions like Ranbaxy. The company's strategy is built on a dual engine: dominating the complex generics market while accelerating growth in high-margin specialty products and novel drug delivery systems across key therapeutic areas like dermatology, ophthalmology, and oncology.

About Fortress Biotech

Fortress Biotech operates as a biopharmaceutical accelerator, leveraging a capital-efficient model to build a diversified portfolio of commercial and development-stage assets. Its strategy centers on acquiring overlooked assets and advancing them either internally or through subsidiary/partner companies, where it retains significant equity and royalty stakes. Recent achievements include the FDA approval of ZYCUBO® for Menkes disease and the $205 million monetization of the associated Priority Review Voucher, demonstrating its ability to create and capture substantial value. The company's value is multi-faceted, derived from product revenue, equity holdings, and structured financial returns from its network.

Therapeutic Areas